• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Celgene Corporation , Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project

    Celgene Corporation , Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project

  2. Regenacy Pharmaceuticals to be Launched by Acetylon Pharmaceuticals and Celgene Corporation Agrees to Complete Acquisition of Acetylon

    Regenacy Pharmaceuticals to be Launched by Acetylon Pharmaceuticals and Celgene Corporation Agrees to Complete Acquisition of Acetylon

  3. Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December

    Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December

  4. Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology

    Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology

  5. UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

    UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

  6. UPDATE: Bull trend intact: S&P 500 rallies -2-

    UPDATE: Bull trend intact: S&P 500 rallies -2-

  7. Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology

    Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology

  8. Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL

    Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL

  9. Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)

    Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)

  10. Fitch Affirms Eletrobras' IDRs at 'BB-'; Outlook Revised to Stable

    Fitch Affirms Eletrobras' IDRs at 'BB-'; Outlook Revised to Stable

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.